On the other hand, in our study, treatment with SGLT2 inhibitors did not reduce albuminuria in patients with FD, in contrast to findings from previous large-scale clinical trials in patients with CKD and small case series in those with FD [[19], [20], [21]]. This evidence concerns the gene SLC5A2 and chronic kidney disease.